Colorectal cancer is now the deadliest cancer for those under 50, in grim milestone

An American Cancer Society analysis of National Center for Health Statistics data covering more than 1 million people from 1990–2023 finds colorectal cancer has risen from the fifth-leading to the leading cause of cancer death among Americans under 50, while lung cancer and leukemia have fallen in rank and breast cancer remains the second-leading cancer death overall and the top cause for females. The report highlights that roughly three in four under-50 patients are diagnosed with advanced disease, urges more research and screening uptake, and notes broader improvements in five‑year cancer survival (about 70% for diagnoses 2015–2021).

Analysis

Market structure: Rapid rise in early-onset colorectal cancer reallocates economic value toward screening, diagnostics and outpatient care. Direct winners: diagnostics and lab names (EXAS, GH, DGX, LH) and targeted-therapy biotech groups with CRC assets (BMY, MRK) that can monetize earlier-stage treatment; losers include providers dependent on late-stage inpatient oncology volume (select hospital REITs/HCA) and incumbents with narrow commodity colonoscopy services. Pricing power will favor proprietary non‑invasive tests if USPSTF/CMS signal broader coverage; commoditized colonoscopy pricing should remain competitive.

Risk assessment: Key tail risks include a CMS reimbursement cut for Cologuard or negative validation studies for liquid biopsies (low prob, high impact within 90–180 days). Immediate (days) impacts are media-driven volume spikes; short-term (weeks–months) depends on payer reactions and guideline discussion; long-term (years) hinge on etiologic research and prevention. Hidden dependencies: screening uptake depends on employer/payer outreach and destigmatization campaigns; overdiagnosis could trigger regulatory backlash.

Trade implications: Tactical, event-driven long exposure to diagnostics: establish a 2–3% position in EXAS (or buy a 3‑month call spread to limit downside) and a 1–2% position in DGX or LH (6–12 month LEAP calls) to capture higher test volumes; pair with a 1% short in HCA or UHS to express shift to outpatient screening. Options: buy EXAS 3‑month 30–50% OTM call spreads or DGX 6‑month ATM calls to play higher volumes and de-risk. Time entries within 2–6 weeks while coverage and awareness are peaking; trim positions on 20–30% gains or after USPSTF/CMS announcements (30–180 days).

Contrarian angles: Consensus misses that increased screening can reduce long‑term drug revenues (negative for late‑stage oncology names) and that prior screening markets (PSA) saw sharp guideline-driven reversals. The market may underprice the regulatory risk to non-invasive tests; historical parallel: PSA-era reimbursement swings suggest material binary outcomes tied to CMS/USPSTF decisions. Unintended consequence: rapid uptake could saturate lab capacity, temporarily raising operational risk and upside for lab-capex beneficiaries (LH, DGX).

Key Decisions for Investors

• Establish a 2–3% long position in Exact Sciences (EXAS) via outright shares or a 3‑month call spread (buy 1x ATM call, sell 1x 30–50% OTM call) to capture near-term screening volume uplift; target +20–30% exit or close after USPSTF/CMS rulings within 30–180 days.
• Add a 1–2% long position in Quest Diagnostics (DGX) or LabCorp (LH) via 6–12 month LEAP calls to play sustained higher diagnostic throughput; sell half on +25% or after quarterly volumes show >5% sequential uplift.
• Implement a 1% pair trade: long EXAS (or DGX) and short 1% HCA Healthcare (HCA) to express outpatient shift; tighten stop-loss at -12% on the short leg and take profits when the diagnostics leg gains >20% or on guideline changes.
• Monitor CMS and USPSTF developments closely: if CMS opens a Medicare coverage review or issues reimbursement guidance in the next 30–90 days, increase/hedge exposure accordingly; if CMS signals reimbursement cuts, reduce EXAS exposure to <1% immediately.